Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30


The PMWC 2022 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.


Confirmed Presenting Companies:

 Speaker Profile

MA, International Economics; CEO, Deep 6 AI

Biography
Wout started his career as a diplomat in the Middle East before joining global management consulting firm, McKinsey & Company, serving a wide variety of industries across Asia. Next, Wout founded an extreme sports adventure company in Singapore and then spent five years in the high-stakes world of international security, growing and leading a 22,000-headcount organization across four continents into a $500M global player. Wout is a frequent speaker on artificial intelligence in healthcare and works closely with hospitals, pharma companies and research institutes on patient recruitment programs.


Clinical & Research Tools Showcase:
Deep 6 AI

Deep 6 AI finds more, better-matching patients for clinical trials in minutes rather than months. Using natural language processing to search unstructured data in medical records, our tool helps healthcare organizations and life sciences companies get life-saving cures to people more quickly.

Precision-matching: The Driver to High-performance Clinical Trials
Learn how a precision matching engine can drive performance throughout the entire clinical trial process. Wout will share the latest metrics & data, real world examples and a couple of surprising insights.

 Speaker Profile

Ph.D., CSO, Truckee Applied Genomics (TAG)

Biography
Dr. Tian Yu is a Molecular Biologist experienced with life science/healthcare startups, currently focusing on leading products development in Truckee Applied Genomics and developing tools to improve the current covid testing by making it more affordable, more reliable, and keeping health care professionals safe from accidental viral exposures. Dr. Yu received her Ph.D. in biochemistry, molecular biology & cell biology in 2018. She has been published on topics such as epigenetic research for the interplay of RNA modifications and circular RNAs in the journal Cell Research. Before joining TAG, Dr. Yu has previously worked as an Assistant Core Director at the Single-Cell Sequencing Core, University of Nevada school of medicine, and then Bioelectronica as the lead biochemist where her research focused on developing life science tools for improving the antibody discovery workflow. The platform which she helped develop is now being placed in research labs across the globe.


Clinical & Research Tools Showcase:
Truckee Applied Genomics (TAG)

Truckee Applied Genomics (TAG) is based in Reno Nevada and develops and manufactures patented reagents to improve molecular tests of tissues and pathogens.

TAG: Cut GIGO to Drive Higher Sample Quality for Molecular Diagnostics
Bio-specimen stability is a challenge in life science research, biotechnology, and medicine, especially when it comes to storing and shipping samples. More dependable ways are needed to protect molecular signatures such as RNA, DNA, and protein from degradation over time, which could introduce pre-analytical variation and compromise results. TAG's technology is designed to allow users to store and transport tissue, cell, and viral samples at room temperature until they are ready for analysis, saving time and money while gaining flexibility in workflow.

 Speaker Profile

Ph.D., Co-Founder and Chief Scientific Officer, Cardea Bio

Biography
Dr. Aran’s current research focuses on creating novel electronic biosensors with true multiomic detection capabilities and applying them to solve real-world problems. She invented CRISPR-ChipTM, which utilizes CRISPR and biology-gated transistors to create the only technology that rapidly detects genes of interest without amplification. CRISPR-Chip™ was the cover of Nature Biomedical Engineering in 2019, featured in over 50 news outlets, and the most read paper that year. CRISPR-Chip™ has since been expanded to detect single-point mutations - published in Nature Biomedical Engineering in 2021. Through Cardea Bio, Dr. Aran’s inventions are being actively developed into commercial products to ensure a lasting impact beyond the academic world. Her research efforts have been recognized by Clinical OMICs 10 under 40 Award, Athena Pinnacle Award, and Nature Research Awards for Inspiring Women in Science. Dr. Aran is also the recipient of numerous grants to develop the next generation of electronic biosensors, including the NSF CAREER Award and multiple NIH RO1 and DARPA grants.


Clinical & Research Tools Showcase:
Cardea Bio

Being able to use Biology as Technology will result in a new generation of natural resources and advanced Powered by Cardea products that have until now been impossible.

All-electronic Infrastructure Leads Way to Real-time Multiomics
A critical challenge faced by systems biology is that multiomics is crippled by the current optical and static approaches all requiring numerous systems. Our all-electronic system unifies multiomics through direct and real-time capture of interactive streams of actionable multiomic data.

 Speaker Profile

PHD, Business Development Associate, NuProbe

Biography
Prior to joining NuProbe, Nicholas Gallerani received his Ph.D. in Pathobiology and Molecular Medicine from Columbia University and was a Fellow at Columbia Technology Ventures, where he assessed new technologies generated by their research labs. His work in biology and neuroscience has led to 4 publications.


Clinical Dx Showcase; NuProbe
NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary technologies to improve the analytical sensitivity of DNA disease biomarkers.

Rapid Custom Development Program for Oncology Translational Research
A look into NuProbe's technology and custom assays to improve analytical sensitivity.

 Speaker Profile

Chief Executive Officer, LevitasBio

Biography
Mr. Pieprzyk is a highly technical life science executive who brings deep knowledge of the Life Science Industry, with extensive experience in single-cell genomics, next-generation sequencing, gene expression, microfluidics, and digital PCR applications. He is also well versed in company development and funding, from inception through IPO process and public company operations.


Clinical & Research Tools Showcase:
LevitasBio

LevitasBio is advancing science and human health by providing researchers with a new and powerful tool for cellular processing and characterization. Our disruptive levitation technology overcomes current technological limitations by providing a gentle, label-free method of purifying, enriching and characterizing specific cell populations.

Empowering the Next Generation of Cellular Analysis
Founded on proprietary label-free levitation technology, LevitasBio has delivered the first truly novel approach to cellular analysis in 30 years. Researchers can now isolate and rescue high quality cells of interest while ensuring the integrity of downstream data and analysis is maintained.

 Speaker Profile

VP of Clinical Operations, Sano Genetics

Biography
Clinical trial executive, passionate about speeding up the clinical trial process. Specialising in enrolment solutions at the intersection of patient recruitment, site management and clinical innovation.


Clinical & Research Tools Showcase:
Sano Genetics

Sano Genetics supports pharma and biotech organisations to accelerate research and clinic trials through its patient-friendly digital platform, enabling effortless onboarding, screening, consent and patient engagement all in one place.

Enabling Precision Medicine Trials in Movement Disorders
To be successful, precision medicine trials must recruit patients informed by the patient’s unique genetic information. We will present a real-world example of a program in the movement disorder setting that successfully identified and tested patients for precision medicine trials.

 Speaker Profile

MS, Program and Operations Manager, Engage Health

Biography
As Program and Operations Manager of Engage Health, Austin leads efforts in trial-enabling protocols and health research in the rare disease space. Austins background in neuroscience and biomedical engineering, plus extensive experience supporting precision medicine trials through genetic testing, caregiver/patient identification and clinical trial recruitment prove useful to clients as they work to advance their programs in rare and complex conditions. Experienced in the challenges facing those developing rare disease therapies, he uses relationships built up over the years as well as Engage Healths EnCompass(R) database to efficiently address business challenges.


Clinical Dx Showcase:
Engage Health, Inc.

Engage Health is a health research firm specializing in rare diseases. Expertise in caregiver and patient identification, support of genetic testing, and other trial-enabling services.

Enabling Precision Medicine Trials Through Genetic Testing
Case study: program which successfully increased awareness/utilization of genetic testing, enabling clinical trials in Parkinson's disease.

 Speaker Profile

MHA, Executive Vice President & General Manager, Clinical Services Business Unit, Guardian Research Network

Biography
Adam has improved clinical research by developing and leading strategies at a large CRO, a renowned site network, and a boutique CRO which he co-founded. At GRN, he leads clinical monitoring, data management, study feasibility and startup, patient eligibility, and study closeout, and is the primary account executive for GRN’s diagnostics clients. He also ensures GRN’s proprietary, HIPAA-compliant technology is fit-for-purpose to accelerate clinical trials.


Clinical & Research Tools Showcase:
Guardian Research Network

A nationwide hospital consortium, Guardian Research Network (GRN) is a 501(c)(3) nonprofit focused on accelerating cures for life-threatening diseases by bringing clinical trials to local communities.

Next-generation CRO: Marrying Contract Research & Real World Data

 Speaker Profile

Head of Oncology Informatics, Inspirata Inc.

Biography
Jesse is an experienced HIT sales leader, currently leading the Cancer Informatics team for Inspirata. He and his colleagues deliver high-caliber AI/NLP, Cancer Registry, and Clinical Trial Matching products, with a dedicated focus on improving patient outcomes. Prior to Inspirata, Jesse led a sales organization at Provation Medical, which is the industry-leading software organization for multidisciplinary clinical procedure documentation. He has helped several companies navigate through the shift from on-premises to SaaS-based business models while always focusing first on customer needs. When not at the office, Jesse is a passionate fly-fisherman, husband, and father of four beautiful girls.


Clinical & Research Tools Showcase:
Inspirata®, Inc.

Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. Our comprehensive cancer informatics solutions bring disparate data together throughout the entire cancer care journey to drive informed decisions that improve survivorship.

The Future of Clinical Trial Matching Is Digital
Inspirata has leveraged its expertise in oncology informatics and its industry-leading AI / NLP technology to create a clinical trial matching solution that truly addresses healthcare institutions’ needs. Come to our showcase to find out what makes Trial Navigator unique.

 Speaker Profile

Ph.D., CSO, Notable Labs

Biography
Joe has been working in biotech for nearly 20 years and was previously Executive Director of the University of California Drug Discovery Consortium (UC-DDC). A pharmacologist by training, Joe has spent the majority of his biotechnology industry career focused on building teams and organizations primarily focused on developing small molecule and biologic therapeutics from bench studies through to Phase II clinical trials at companies including BriaCell Therapeutics, OncoCyte and Cell Targeting, where he served in CEO/CTO roles.


Clinical & Research Tools Showcase:
Notable Labs

Notable is a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, a new class of medicines. Notable aims to revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient, and cancer by cancer.

Advancing Predictive Precision Medicine Using Functional Approach
Although genomic- and biomarker-driven precision medicine strategies have improved outcomes for those patients with certain disease characteristics, most cancer patients lack actionable mutations or biomarkers. Predictive precision medicine utilizing a functional, ex vivo approach offers hope for those patients.

 Speaker Profile

Ph.D., Chief Science Officer, Fluidigm Corporation

Biography
Dr. Quong is the Chief Science Officer, and he serves as liaison and bridge to the research community, identifying opportunities to address unmet needs in human health. He is the primary point of contact to pharma industry consortia and other avenues of global collaboration and plays a key role on establishing product roadmaps and broad product development priorities as well as potential partnership, licensing, and acquisition opportunities. Previously he was the Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research and was a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. His research focused on systems biology approaches to understanding mechanisms of resistance to treatment of breast cancer and biomarkers of response. He has published extensively and served on the editorial boards of Cancer Research and The American Journal of Pathology.


Clinical & Research Tools Showcase:
Fluidigm

Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all.

Reimagining High-content Immune Profiling for Clinical Research
Time and samples are precious commodities when it comes to clinical research, particularly for large cohorts.  Learn about the advantages of easy workflows for high-parameter assays, minimal sample volumes and automated analysis with Fluidigm’s CyTOF XT® and immune profiling solutions.

 Speaker Profile

Field Application Scientist, Sengenics

Biography
Joseph Miseirvitch is a scientist with a passion for solving the unknowns in cellular, molecular, and biological pathways with over 10 years of experience in the life sciences. He is currently the Field Application Scientist for Sengenics covering North America.


Clinical & Research Tools Showcase:
Sengenics

Sengenics is a precision medicine company founded in the desire to improve patient outcomes based on physiologically relevant, data-guided, decision making. Our platform enables the discovery and validation of autoantibody biomarker signatures for patient stratification, drug response prediction and development of companion diagnostics.

Autoantibody Biomarkers - Response Prediction in Immuno-Oncology
The understanding of the immune response to cancer can be harnessed to better comprehend outcomes and response to therapeutics. Sengenics platform enables discovery and validation of highly predictive autoantibody biomarker signatures for guiding treatment decision making.

 Speaker Profile

Director of Sales & Marketing, Watson Bio Lab

Biography
Laboratory Supplies & Consumables by Watson Bio Lab is a US subsidiary of Fukae Kasei, Co., Ltd. Fukae Kasei/Watson is one of the leading manufactures of Laboratory Supplies & Consumables. I am very much looking forward to introducing you to our products very soon.


Clinical & Research Tools:
Watson Bio Lab

One of the leading manufactures of laboratory supplies and consumables in Japan. We offer Micropipettes, Pipette Tips, Filter Pipette Tips, Repetitive Pipettes, Cell Culture Plates, PCR-related products, and much more. OEM projects welcome.

Small Rolls and Big Impact
We manufacture Micropipettes, Pipette Tips, Filter Pipette Tips, Repetitive Pipettes, Cell Culture Plates, PCR-related products in Japan. While our products play small roles in research, however, some of our customers worldwide are very satisfied with their results which our products led the accuracy.

 Speaker Profile

Ph.D., Vice President of Business Development, Pear Bio

Biography
Dr Schlicher leads corporate strategy for business development at Pear Bio. She recently led strategy and launch for Genialis ResponderIDTM (2021). She brings over 20 years of experience in precision medicine, diagnostics, and entrepreneurial leadership. Robyn has patented inventions in regenerative medicine and is a recognized global expert in advanced analytical techniques. Her publication on drug delivery by targeted cavitation has been widely cited and highlighted worldwide. She earned her doctorate in bioengineering from Georgia Institute of Technology and Emory University, receiving National Institutes of Health and Medtronic fellowships. In 2021, Robyn became an inaugural fellow of On Deck Health (ODH1).


Clinical & Research Tools Showcase:
Pear Bio

At Pear Bio, we evaluate cancer drug efficacy using organ-on-a-chip and computer vision to monitor cancer progression of patient-derived tumor samples against potential treatment options. We inform physicians to guide treatment decisions and provide tools to help pharmaceutical companies develop new therapies.

Ex Vivo Imaging AI for Cancer Treatment Guidance
Pear Bio cultures patient tumor samples ex vivo and tests potential treatment options. A proprietary computer vision pipeline finds image-based biomarkers in time-course 3D microscopy data of patient tumor cultures. The platform has applications in guiding treatment decision-making and therapeutics development.

 Speaker Profile

Account Manager, Collaborative Drug Discovery

Biography
Lauren recently entered the Digital & Advanced Analytics market as a new business development representative for Collaborative Drug Discovery (CDD). In her first 3 years she has focused on helping organizations implement state of the art digital workflows through the implementation of cloud-based research data storage and analytics solutions. As a CDD Vault Account Manager, Lauren helps R&D organizations better understand how they can store, analyze and share their research results.


Clinical & Research Tools Showcase:
Collaborative Drug Discovery

CDD advances science through better data management. It’s CDD Vault® product, is a hosted informatics solution that allows researchers to organize data and experiments and securely collaborate in real time. CDD also offers BioHarmony™ Drug Data Store and Annotator an ML assisted bioassay annotation platform.

Challenges of storing R&D data for novel biologics
New CDD Vault features for efficient storage and analysis of R&D result data for biological entities.

 Speaker Profile

Ph.D., DVM, Post Doctoral Fellow, Stanford University

Biography
John studied at the University of London’s, Royal Veterinary College where he earned a degree in veterinary medicine and continued his education at Stanford University where he obtained a PhD in genetics. John is now a postdoc in the Euan Ashley lab at Stanford university and is interested in utilizing long read (nanopore) genome sequencing to improve the health of human and non-human patients.

Talk
Ultra-rapid Nanopore Genome Sequencing in a Critical Care Setting
Genetic disease is a major contributor to critical care hospitalizations. Early genetic diagnosis can guide clinical management, yet the turnaround time for whole genome diagnostic testing is commonly months. We aimed to reduce the turn-around time for whole genome sequencing diagnostic test to be hours enabling rapid clinical decision making required for critically ill patients.


 Speaker Profile

Ph.D., Founder & CEO, INanoBio Inc

Biography
Dr. Bharath Takulapalli is Founder & CEO of INanoBio, a startup developing advanced technologies at the interface of nanotechnology, biology and machine learning (ML) for future Healthcare 2.0. He believes that, as a scientific community, we can preempt 90% of all diseases. Disease preemption implies detection in pre-disease stages, followed by early intervention and cure, before full disease onset. However, we do not have the technology tools to achieve this today. To contribute, at INanoBio we are developing two product platforms to extract 100x more information from systems biology (genotype and phenotype) than currently possible. First is a novel semiconductor nanopore transistor device to sequence the DNA 100X faster than state of art, at 1/10th the cost. The second is a first-of-kind multiplexed protein biosensor technology termed SPOC (sensor integrated proteome on chip) to study protein interactions at scale. INanoBio is based out of Menlo Park, California and Scottsdale, Arizona.


Clinical & Research Tools Showcase:
INanoBio Inc

INanoBio is a DARPA funded company developing technologies at the interface of nanotechnology, biology and machine learning. In addition to FENT nanopore-transistor technology for 100x faster DNA sequencing, INanoBio is developing first-of-kind sensor integrated proteome on chip (SPOC) platform to screen protein interactions at scale.

Novel Solid-state Nanopore-transistor for 100x DNA Sequencing
INanoBio is developing novel Field Effect Nanopore Transistor (FENT) technology to sequence DNA 100x faster than state-of-art.